CY1106092T1 - Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2 - Google Patents

Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2

Info

Publication number
CY1106092T1
CY1106092T1 CY20061100719T CY061100719T CY1106092T1 CY 1106092 T1 CY1106092 T1 CY 1106092T1 CY 20061100719 T CY20061100719 T CY 20061100719T CY 061100719 T CY061100719 T CY 061100719T CY 1106092 T1 CY1106092 T1 CY 1106092T1
Authority
CY
Cyprus
Prior art keywords
ptx3
growth factor
treatment
diseases caused
petraxin
Prior art date
Application number
CY20061100719T
Other languages
English (en)
Inventor
A. Mantovani
B. Bottazzi
M. Presta
M. Rusnati
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of CY1106092T1 publication Critical patent/CY1106092T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Περιγράφεται η χρήση της μακριάς πεντραξίνης ΡΤΧ3 (ΡΤΧ3) ή ενός λειτουργικού παραγώγου της για την παρασκευή ενός φαρμάκου το οποίο αναστέλλει την βιολογική δράση του αυξητικού παράγοντα FGF-2, για την πρόληψη και θεραπεία ασθενειών που προκαλούνται από μια μεταβαλλόμενη ενεργοποίηση του εν λόγω αυξητικού παράγοντα FGF-2.
CY20061100719T 2000-11-08 2006-06-05 Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2 CY1106092T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000578A IT1317930B1 (it) 2000-11-08 2000-11-08 Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PCT/IT2001/000563 WO2002038169A1 (en) 2000-11-08 2001-11-08 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Publications (1)

Publication Number Publication Date
CY1106092T1 true CY1106092T1 (el) 2011-06-08

Family

ID=11454983

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100719T CY1106092T1 (el) 2000-11-08 2006-06-05 Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2

Country Status (22)

Country Link
US (1) US7858577B2 (el)
EP (1) EP1331940B1 (el)
JP (1) JP4167061B2 (el)
KR (1) KR100822357B1 (el)
CN (1) CN1304047C (el)
AT (1) ATE322906T1 (el)
AU (2) AU2251302A (el)
BR (1) BR0115190A (el)
CA (1) CA2428176C (el)
CY (1) CY1106092T1 (el)
CZ (1) CZ299673B6 (el)
DE (1) DE60118769T2 (el)
DK (1) DK1331940T3 (el)
ES (1) ES2261515T3 (el)
HK (1) HK1061209A1 (el)
HU (1) HU229100B1 (el)
IT (1) IT1317930B1 (el)
MX (1) MXPA03004005A (el)
PL (1) PL205925B1 (el)
PT (1) PT1331940E (el)
SK (1) SK287791B6 (el)
WO (1) WO2002038169A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
JP4667372B2 (ja) * 2004-02-25 2011-04-13 株式会社ペルセウスプロテオミクス 血管障害の程度の判定方法
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
WO2007085412A1 (en) * 2006-01-24 2007-08-02 Tecnogen S.P.A. Fgf2-binding peptides and uses thereof
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
MX2008013872A (es) 2006-05-02 2008-11-14 Sigma Tau Ind Farmaceuti Uso de timosina alfa 1, sola o en combinacion con ptx3 o ganciclovir, para el tratamiento de infeccion por citomegalovirus.
EP2865384B1 (en) * 2012-06-22 2018-08-15 The University of Tokyo Agent for treating or preventing systemic inflammatory response syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1235392A (en) * 1991-01-14 1992-08-17 New York University Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

Also Published As

Publication number Publication date
PL205925B1 (pl) 2010-06-30
SK5622003A3 (en) 2003-10-07
MXPA03004005A (es) 2004-05-05
ITRM20000578A1 (it) 2002-05-08
US7858577B2 (en) 2010-12-28
EP1331940A1 (en) 2003-08-06
CZ299673B6 (cs) 2008-10-15
ES2261515T3 (es) 2006-11-16
WO2002038169A1 (en) 2002-05-16
JP4167061B2 (ja) 2008-10-15
DK1331940T3 (da) 2006-08-14
HUP0400541A3 (en) 2006-01-30
IT1317930B1 (it) 2003-07-15
HU229100B1 (en) 2013-07-29
HUP0400541A2 (hu) 2004-05-28
ATE322906T1 (de) 2006-04-15
JP2004513151A (ja) 2004-04-30
AU2002222513B8 (en) 2006-11-23
AU2002222513B2 (en) 2006-10-26
KR100822357B1 (ko) 2008-04-16
KR20030061396A (ko) 2003-07-18
AU2251302A (en) 2002-05-21
US20040023879A1 (en) 2004-02-05
HK1061209A1 (en) 2004-09-10
CA2428176C (en) 2013-02-05
DE60118769D1 (de) 2006-05-24
PT1331940E (pt) 2006-07-31
CZ20031179A3 (cs) 2003-11-12
PL365292A1 (en) 2004-12-27
SK287791B6 (sk) 2011-10-04
EP1331940B1 (en) 2006-04-12
CN1473050A (zh) 2004-02-04
CN1304047C (zh) 2007-03-14
DE60118769T2 (de) 2007-01-04
CA2428176A1 (en) 2002-05-16
BR0115190A (pt) 2004-02-03

Similar Documents

Publication Publication Date Title
CY1106092T1 (el) Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
ES2485940T3 (es) Combinación de vacunas contra Meningitis B/C
ITFI20000168A0 (it) Un ago del tipo da biopsia o per altri prelievi da organi umani o di animali.
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
DE59203983D1 (de) Endoskopische Koagulationsfasszange.
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY1105000T1 (el) Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη
BRPI0313733A8 (pt) Uso da proteína n beta cinase
CY1106733T1 (el) Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη
BR0112565A (pt) Biomaterial que inclui tecido da córnea de animais
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
CY1109221T1 (el) Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
DE69814394D1 (de) Verwendung von levobupivacain
CY1111509T1 (el) Ενωσεις με ιδιοτητες απελευθερωσης αυξητικης ορμονης
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
CY1115194T1 (el) Χρηση της μακρας πεντραξινης ptx3 για την προληψη ή θεραπεια ιικων ασθενειων
CY1105116T1 (el) Χρηση των il-6r/il-6 χιμαιρων στη νοσο του huntington
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων